source
- Biotech Index Surges as IPOs and M&A Activity Accelerate in 2026The XBI biotech index, which had fallen to about $64 per share three years ago, has climbed back to near $170, almost doubling its value over the past year. Investor interest is reflected in a wav…
- BioNTech-Genentech halts colorectal cancer vaccine trial after higher death rate in vaccine armBioNTech and Genentech stopped a phase 2 trial of their personalized mRNA vaccine BNT122 in patients with stage 2 or 3 colorectal cancer after an independent data safety monitoring board found more…